Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68-DOTA-minigastrin - Novartis

Drug Profile

Gallium-68-DOTA-minigastrin - Novartis

Alternative Names: 68Ga-DOTA-MGS5; 68Ga-labelled [DOTA0,DGlu1,desGlu2-6,(N-Me)Nle11,1-Nal13]minigastrin; 68Ga-labelled minigastrin analogue; Gallium-68-DOTA-MGS5

Latest Information Update: 15 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Imaging agents; Peptides; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Neuroendocrine tumours

Most Recent Events

  • 30 Jun 2023 Novartis in collaboration with Medical University Innsbruck completes a phase I/II trial in Neuroendocrine tumours (Diagnosis) in Austria (IV) (NCT06155994)
  • 16 Jun 2021 Pharmacodynamics data from a preclinical trial in Neuroendocrine tumours released by Medical University of Innsbruck
  • 20 Jan 2021 Phase-I/II clinical trials in Neuroendocrine tumours (Diagnosis) in Austria (IV) (NCT06155994)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top